We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.75B
AUM Growth
-$879M
Cap. Flow
-$770M
Cap. Flow %
-44.05%
Top 10 Hldgs %
36.57%
Holding
112
New
6
Increased
25
Reduced
47
Closed
16

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$12.8M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$12M
3
EVH icon
Evolent Health
EVH
+$6.42M
4
MRUS
Merus
MRUS
+$3.85M
5
ACHC icon
Acadia Healthcare
ACHC
+$3.72M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$63M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$55.9M
3
FRPT icon
Freshpet
FRPT
+$48.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$41.7M
5
UNH icon
UnitedHealth
UNH
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
2 Consumer Staples 0%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.4B
$104M 5.95%
175,750
-53,850
-23% -$34M
LLY icon
2
Eli Lilly
LLY
$1.02T
$93.7M 5.36%
113,500
-31,000
-21% -$25.8M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$89.2M 5.1%
1,007,569
-89,330
-8% -$8.71M
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$10.8B
$55.2M 3.16%
166,698
-98,514
-37% -$32.4M
UNH icon
5
UnitedHealth
UNH
$376B
$52.6M 3.01%
100,500
-75,500
-43% -$38.6M
TVTX icon
6
Travere Therapeutics
TVTX
$5.2B
$52.3M 3%
2,921,196
-2,052,453
-41% -$41.7M
ISRG icon
7
Intuitive Surgical
ISRG
$127B
$50.5M 2.89%
102,000
-114,000
-53% -$63M
RARE icon
8
Ultragenyx Pharmaceutical
RARE
$2.45B
$50.5M 2.89%
1,394,434
-345,379
-20% -$14.4M
PEN icon
9
Penumbra
PEN
$12.7B
$45.7M 2.62%
171,000
-69,000
-29% -$18.7M
RVMD icon
10
Revolution Medicines
RVMD
$39.9B
$45.3M 2.59%
1,281,640
+68,383
+6% +$2.78M
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$6.81B
$44.2M 2.53%
834,188
-328,530
-28% -$18.2M
MIRM icon
12
Mirum Pharmaceuticals
MIRM
$6.46B
$42.9M 2.45%
951,765
-519,799
-35% -$24.5M
MRUS
13
DELISTED
Merus
MRUS
$41.3M 2.36%
980,751
+88,202
+10% +$3.85M
INSM icon
14
Insmed
INSM
$21.4B
$39.4M 2.25%
515,900
-34,100
-6% -$2.61M
ALNY icon
15
Alnylam Pharmaceuticals
ALNY
$27.5B
$38.7M 2.21%
143,250
-112,950
-44% -$29M
ASND icon
16
Ascendis Pharma A/S
ASND
$16B
$33.7M 1.93%
216,000
-89,000
-29% -$12.7M
ZLAB icon
17
Zai Lab
ZLAB
$2.06B
$32.7M 1.87%
904,592
-400,745
-31% -$12.3M
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.06B
$31.3M 1.79%
931,681
-320,178
-26% -$12.2M
NBIX icon
19
Neurocrine Biosciences
NBIX
$16.8B
$30.9M 1.77%
279,000
-441,500
-61% -$55.9M
NUVL
20
DELISTED
Nuvalent
NUVL
$30.3M 1.73%
427,532
-2,462
-0.6% -$193K
AGL icon
21
Agilon Health
AGL
$1.53B
$30.1M 1.72%
278,000
-20,532
-7% -$1.79M
PHR icon
22
Phreesia
PHR
$663M
$29.4M 1.68%
1,148,336
-891,664
-44% -$24.2M
BSX icon
23
Boston Scientific
BSX
$69.5B
$27.9M 1.6%
277,000
-183,000
-40% -$18.4M
AKRO
24
DELISTED
Akero Therapeutics
AKRO
$27.2M 1.56%
672,759
-273,740
-29% -$11.6M
DXCM icon
25
DexCom
DXCM
$31.5B
$27.2M 1.55%
397,650
+44,650
+13% +$3.64M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Rock Springs Capital Management held 112 positions worth $1.75B, down 33% from $2.63B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management withdrew a net $770M in Q1 2025, closing 16 positions and reducing 47 holdings. Its most notable exit was Freshpet, an estimated $48.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Danaher worth $12.1M.

  • Rock Springs Capital Management's largest Q1 2025 buy was Danaher: 58,800 shares worth $12.1M.
  • Rock Springs Capital Management added most to Tarsus Pharmaceuticals in Q1 2025, an estimated $12M increase.
  • Rock Springs Capital Management's biggest Q1 2025 reduction was Intuitive Surgical, cutting an estimated $63M.
  • Rock Springs Capital Management fully exited Freshpet in Q1 2025, selling an estimated $48.5M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $1.75B portfolio in Q1 2025.
  • Rock Springs Capital Management opened 6 new positions and closed 16 in Q1 2025.
  • Rock Springs Capital Management's portfolio value fell 33% quarter-over-quarter to $1.75B.

Based on Rock Springs Capital Management's 13F filing for Q1 2025, filed 15 May 2025.